Production (Stage)
Aurinia Pharmaceuticals Inc.
AUPH
$7.99
-$0.16-1.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,533.59% | -90.04% | 1,887.53% | 106.72% | 60.00% |
| Total Depreciation and Amortization | -0.12% | -0.63% | 1.03% | -0.08% | -2.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -243.56% | -86.35% | 118.77% | 332.40% | -111.51% |
| Change in Net Operating Assets | -211.09% | 286.53% | -308.48% | 153.72% | -155.38% |
| Cash from Operations | -95.68% | 76.84% | 7.49% | 185.19% | -229.95% |
| Capital Expenditure | 93.95% | -- | -- | -- | 95.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.40% | 473.67% | 72.63% | -178.43% | 926.54% |
| Cash from Investing | -20.88% | 471.01% | 72.63% | -178.45% | 886.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 8.55% | -2.43% | 8.22% | -16.02% | 57.54% |
| Issuance of Common Stock | 17.24% | 3,256.78% | -78.23% | -80.38% | 70.23% |
| Repurchase of Common Stock | -99.92% | -- | 100.00% | 65.53% | -680.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -114.08% | -746.66% | 67.10% | 45.03% | -169.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.74% | 1,139.38% | 112.03% | -299.26% | 528.89% |